Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Last trade$38.26
Day change-$0.35 (-0.91%)
Day range$37.41 – $39.17
Volume3,301,669
Market cap$27.98B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$27.98B
Price / earnings
—
Price / book
6.96×
Price / sales
680.96×
EV / sales
640.99×
EV / EBITDA
-19.86×
Profitability
Earnings per share
-$0.48
Return on assets
-6.92%
Return on equity
-8.57%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.56×
Quick ratio
15.56×
Cash ratio
5.87×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$39.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ROIV, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$35.12M
$1.44M
$2.52M
$2M
$1.57M
$2.17M
$7.57M
$9.02M
Cost of revenue
$3.35M
$0
$0
$0
$111K
$0
$0
$0
Gross profit
$31.77M
$1.44M
$2.52M
$2M
$1.46M
$2.17M
$7.57M
$9.02M
Selling, general and administrative
$154.08M
$165.53M
$158.25M
$175.07M
$143.13M
$134.02M
$147.09M
$141.55M
Research and development
$145.75M
$202.02M
$198.95M
$165.38M
$164.57M
$152.92M
$145.24M
$141.6M
Total operating expenses
$299.82M
$367.44M
-$412.72M
$341.15M
$307.69M
$287.09M
$292.54M
$283.4M
Operating income
-$268.05M
-$365.99M
$415.24M
-$339.15M
-$306.23M
-$284.92M
-$284.97M
-$274.38M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$166.35M
-$294.56M
$454.1M
-$290.37M
-$159.04M
-$269.26M
-$203.05M
-$234.51M
Income taxes
-$13.37M
-$3.96M
$98.35M
$23.33M
$7M
$4.65M
$49.32M
-$25.57M
Net income
-$137.21M
-$290.61M
$355.74M
-$313.7M
-$166.04M
-$273.91M
-$252.38M
$118.08M
Net income attributable to common shareholders
-$191.62M
-$189.84M
$302.99M
-$265.89M
-$113.52M
-$223.36M
-$206.48M
$169.38M
EBITDA
-$267.45M
-$365.79M
-$354.36M
-$338.46M
-$305.31M
-$283.82M
-$283.54M
-$271.46M
Basic earnings per share
-$0.27
-$0.26
$0.42
-$0.38
-$0.17
-$0.33
-$0.29
$0.23
Diluted earnings per share
-$0.27
-$0.26
$0.42
-$0.38
-$0.17
-$0.33
-$0.31
$0.23
Recent news
Company coverage with links to the original publishers.
Roivant Sciences (ROIV) reported a quarterly loss of $0.19 per share, beating consensus estimates of $0.41 loss by 53.66%. The company's revenues reached $35.12 million, significantly surpassing estimates. Despite strong year-to-date performance of 79.2% versus the S&P 500's 7.8%, the stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026 on November 9, 2026, with a conference call hosted by majority stockholder Roivant Sciences. The company is a clinical-stage immunology firm developing anti-FcRn targeted therapies for autoimmune diseases, with ongoing clinical studies in Graves' disease, myasthenia gravis, and CIDP.
Roivant and Priovant announced positive Phase 3 results for brepocitinib in treating non-infectious uveitis. The drug met primary and secondary endpoints in both CLARITY-1 and CLARITY-2 trials, with 62% of patients achieving steroid-free quiescence at Week 48 compared to 20% on placebo. The companies plan to file a supplemental New Drug Application in the first half of 2027.
Several stocks experienced significant price movements based on recent developments. QUALCOMM rose 3.2% following a data center partnership with AWS and positive AI growth outlook. Roivant Sciences surged 18.8% after positive Phase 2 results for its pulmonary hypertension drug. Bloom Energy gained 9.6% after being added to the S&P 500. However, Novartis tumbled 13.9% after its del-desiran drug failed to meet Phase 3 trial expectations for myotonic dystrophy treatment.
Lindus Therapeutics, a drug development company focused on in-licensed assets, has appointed Dr. Gillian Cannon as a non-executive director. Cannon brings over 30 years of biopharmaceutical commercial leadership experience from roles at Merck and Roivant Sciences. She will help shape the company's commercial strategy as it builds its portfolio of clinical-stage assets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.